ARVN insider trading
NasdaqGS HealthcareARVINAS, INC. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About ARVINAS, INC.
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 3 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company's products also consists ARV 393, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes which is in Phase 1 first-in-human clinical trial; ARV 102 for the treatment of neurodegenerative diseases, which is in Phase 1 clinical trial; and KRAS G12D program is in preclinical development for pancreatic and colorectal cancers. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Company website: www.arvinas.com
ARVN insider activity at a glance
FilingIQ has scored 372 insider transactions for ARVN since Oct 1, 2018. The most recent filing in our index is dated May 11, 2026.
Across the full history, 23 open-market purchases
and 199 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on ARVN insider trades is 57.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest ARVN Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading ARVN
Frequently asked
- How many insider trades does FilingIQ track for ARVN?
- FilingIQ tracks 372 Form 4 insider transactions for ARVN (ARVINAS, INC.), covering filings from Oct 1, 2018 onwards. 26 of those were filed in the last 90 days.
- Are ARVN insiders net buyers or net sellers?
- Across the full Form 4 history for ARVN, 23 transactions (6%) were open-market purchases and 199 (53%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does ARVN insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is ARVN in?
- ARVINAS, INC. (ARVN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $867.80M.
Methodology & sources
Every ARVN insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.